PD-1 Blockade Restores Impaired Function of Ex Vivo Expanded CD8 T Cells and Enhances Apoptosis in Mismatch Repair Deficient EpCAMPD-L1 Cancer Cells
Overview
Authors
Affiliations
Background: Adoptive T cell therapy has been proven to be a promising modality for the treatment of cancer patients in recent years. However, the increased expression of inhibitory receptors could negatively regulate the function and persistence of transferred T cells which mediates T cell anergy, exhaustion, and tumor regression. In this study, we investigated increased cytotoxic activity after the blockade of PD-1 for effective immunotherapy.
Methods: The cytotoxic function of expanded CD8 CTLs and interactions with tumor cells investigated after blocking of PD-1. Ex vivo expanded CD8 CTLs were co-cultured with mismatch repair (MMR) stable or deficient (high microsatellite instability [MSI-H]) EpCAM tumor cells. The levels of IFN-γ and GrB were detected by enzyme-linked immunosorbent spot assay. Flow cytometry and confocal microscopy were used to assess CD107a mobilization, cytosolic uptake, and cell migration.
Results: A dramatic increase in PD-1 expression on the surface of CD8 CTLs during ex vivo expansion was observed. PD-1 level was downregulated by approximately 40% after incubation of the CD8 CTLs with monoclonal antibody which enhanced the secretion of IFN-γ, GrB, and CD107a. Additionally, PD-1 blockade enhanced cell migration and cytosolic exchange between CD8 CTLs and MMR deficient (MSI-H) EpCAMPD-L1 tumor cells.
Conclusion: The blockade of PD-1 enhanced the cytotoxic efficacy of CD8 CTLs toward MMR deficient tumor cells. In conclusion, we propose that blocking of PD-1 during the expansion of CD8 CTLs may improve the clinical efficacy of cell-based adoptive immunotherapy.
Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F Mol Cancer. 2024; 23(1):9.
PMID: 38195537 PMC: 10775503. DOI: 10.1186/s12943-023-01925-5.
Lee S, Lee S, Cho H, Min K, Hong J, Song J Int J Mol Sci. 2023; 24(2).
PMID: 36674491 PMC: 9865129. DOI: 10.3390/ijms24020974.
Inanaga S, Igase M, Sakai Y, Hagimori K, Sunahara H, Horikirizono H J Vet Intern Med. 2022; 36(5):1760-1769.
PMID: 35959511 PMC: 9511092. DOI: 10.1111/jvim.16454.
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.
Thibaudin M, Limagne E, Hampe L, Ballot E, Truntzer C, Ghiringhelli F Cancer Immunol Immunother. 2022; 71(10):2549-2563.
PMID: 35292828 PMC: 10992601. DOI: 10.1007/s00262-022-03182-9.
Lin Z, Wen M, Yu E, Lin X, Wang H, Chen J Front Cell Dev Biol. 2021; 9:659080.
PMID: 34422796 PMC: 8371204. DOI: 10.3389/fcell.2021.659080.